Status of research and development of vaccines for Streptococcus pyogenes

Andrew C. Steer; Jonathan R. Carapetis; James B. Dale; John D. Fraser; Michael F. Good; Luiza Guilherme; Nicole J. Moreland; Edward Kim Mulholland; Florian Schodel; Pierre R. Smeesters

doi:10.1016/j.vaccine.2016.03.073

Status of research and development of vaccines for Streptococcus pyogenes

Andrew C. Steer, Jonathan R. Carapetis, James B. Dale, John D. Fraser, Michael F. Good, Luiza Guilherme, Nicole J. Moreland, Edward Kim Mulholland, Florian Schodel, Pierre R. Smeesters

Research output: Contribution to journal › Article › peer-review

Abstract

Streptococcus pyogenes is an important global pathogen, causing considerable morbidity and mortality, especially in low and middle income countries where rheumatic heart disease and invasive infections are common. There is a number of promising vaccine candidates, most notably those based on the M protein, the key virulence factor for the bacterium. Vaccines against Streptococcus pyogenes are considered as impeded vaccines because of a number of crucial barriers to development. Considerable effort is needed by key players to bring current vaccine candidates through phase III clinical trials and there is a clear need to develop a roadmap for future development of current and new candidates.

Original language	English
Pages (from-to)	2953-2958
Number of pages	6
Journal	Vaccine
Volume	34
Issue number	26
DOIs	https://doi.org/10.1016/j.vaccine.2016.03.073
Publication status	Published - 3 Jun 2016
Externally published	Yes

Access to Document

10.1016/j.vaccine.2016.03.073Licence: CC BY

Cite this

@article{505c1e7485fa47cd8706e2b61b137ff0,

title = "Status of research and development of vaccines for Streptococcus pyogenes",

abstract = "Streptococcus pyogenes is an important global pathogen, causing considerable morbidity and mortality, especially in low and middle income countries where rheumatic heart disease and invasive infections are common. There is a number of promising vaccine candidates, most notably those based on the M protein, the key virulence factor for the bacterium. Vaccines against Streptococcus pyogenes are considered as impeded vaccines because of a number of crucial barriers to development. Considerable effort is needed by key players to bring current vaccine candidates through phase III clinical trials and there is a clear need to develop a roadmap for future development of current and new candidates.",

keywords = "Group A Streptococcus, Rheumatic fever, Streptococcus pyogenes, Vaccine",

author = "Steer, {Andrew C.} and Carapetis, {Jonathan R.} and Dale, {James B.} and Fraser, {John D.} and Good, {Michael F.} and Luiza Guilherme and Moreland, {Nicole J.} and Mulholland, {Edward Kim} and Florian Schodel and Smeesters, {Pierre R.}",

year = "2016",

month = jun,

day = "3",

doi = "10.1016/j.vaccine.2016.03.073",

language = "English",

volume = "34",

pages = "2953--2958",

journal = "Vaccine",

issn = "0264-410X",

publisher = "Elsevier",

number = "26",

}

TY - JOUR

T1 - Status of research and development of vaccines for Streptococcus pyogenes

AU - Steer, Andrew C.

AU - Carapetis, Jonathan R.

AU - Dale, James B.

AU - Fraser, John D.

AU - Good, Michael F.

AU - Guilherme, Luiza

AU - Moreland, Nicole J.

AU - Mulholland, Edward Kim

AU - Schodel, Florian

AU - Smeesters, Pierre R.

PY - 2016/6/3

Y1 - 2016/6/3

N2 - Streptococcus pyogenes is an important global pathogen, causing considerable morbidity and mortality, especially in low and middle income countries where rheumatic heart disease and invasive infections are common. There is a number of promising vaccine candidates, most notably those based on the M protein, the key virulence factor for the bacterium. Vaccines against Streptococcus pyogenes are considered as impeded vaccines because of a number of crucial barriers to development. Considerable effort is needed by key players to bring current vaccine candidates through phase III clinical trials and there is a clear need to develop a roadmap for future development of current and new candidates.

AB - Streptococcus pyogenes is an important global pathogen, causing considerable morbidity and mortality, especially in low and middle income countries where rheumatic heart disease and invasive infections are common. There is a number of promising vaccine candidates, most notably those based on the M protein, the key virulence factor for the bacterium. Vaccines against Streptococcus pyogenes are considered as impeded vaccines because of a number of crucial barriers to development. Considerable effort is needed by key players to bring current vaccine candidates through phase III clinical trials and there is a clear need to develop a roadmap for future development of current and new candidates.

KW - Group A Streptococcus

KW - Rheumatic fever

KW - Streptococcus pyogenes

KW - Vaccine

UR - http://www.scopus.com/inward/record.url?scp=84962162202&partnerID=8YFLogxK

U2 - 10.1016/j.vaccine.2016.03.073

DO - 10.1016/j.vaccine.2016.03.073

M3 - Article

AN - SCOPUS:84962162202

VL - 34

SP - 2953

EP - 2958

JO - Vaccine

JF - Vaccine

SN - 0264-410X

IS - 26

ER -

Status of research and development of vaccines for Streptococcus pyogenes

Abstract

Access to Document

Other files and links

Fingerprint

Cite this